We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline is appealing a $54 million fine from the UK’s Competitions and Market Authority over pay-for-delay allegations, contending the company’s conduct was “objectively justified.” Read More
Pharmacy benefit manager Express Scripts is firing back at Anthem’s $15 billion lawsuit that accuses the PBM of breaching good faith negotiation requirements. Read More
To bridge the gulf between the promise of biosimilars on drug pricing and the reality, payors should incentivize biosimilar utilization, a new report states. Read More
The UK’s National Institute for Health and Care Excellence has recommended reimbursement for PTC Therapeutics’ Translarna for the treatment of Duchenne muscular dystrophy. Read More
It took Pfizer and Allergan less than 48 hours to nix their plan to build one of the world’s largest drugmakers, placing the blame squarely on the U.S. Treasury Department. Read More